Alkermes Stock News

Stock analysts at Citigroup assumed coverage on shares of Alkermes (NASDAQ:ALKS) in a research report issued on Wednesday, The Fly reports. The firm set a neutral rating on the stock. Other research analysts also recently issued reports about the stock. Stifel Nicolaus increased their target price on shares of Alkermes from $25.00 to $29.00 and []

Key Players covered in the Opioid Use Disorder Market Research report are Camurus Pfizer Inc., BioDelivery Sciences International Inc., TEVA PHARMACEUTICALS USA, INC, Orexo US, Inc., Indivior PLC, Hikma Pharmaceuticals, Mylan, Mallinckrodt. , Titan Pharmaceuticals Inc., Alkermes Key Players covered in the Opioid Use Disorder Market Research report are Camurus Pfizer Inc., BioDelivery Sciences International Inc., TEVA PHARMACEUTICALS USA, INC, Orexo US, Inc., Indivior PLC, Hikma Pharmaceuticals, Mylan, Mallinckrodt. , Titan Pharmaceuticals Inc., Alkermes

Analysts expect Alkermes plc (NASDAQ:ALKS) to announce $323.52 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Alkermes earnings, with the highest sales estimate coming in at $327.95 million and the lowest estimate coming in at $316.33 million. Alkermes posted sales of $280.00 million during the []

DUBLIN, Nov. 24, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx Conference on Thu

DUBLIN , Nov. 24, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx Conference on Thursday, Dec. 2, 2021 at 10:30 a.m. ET ( 3:30 p.m. GMT ).

Invesco Ltd. grew its position in Alkermes plc (NASDAQ:ALKS) by 0.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 772,481 shares of the companys stock after purchasing an additional 3,927 shares during the period. Invesco Ltd.s holdings in Alkermes were worth $18,942,000 at the end of the most recent reporting period. Other hedge []

Shares of Alkermes plc (NASDAQ:ALKS) have been given a consensus rating of Hold by the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average twelve-month price objective []

Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.

Related Stocks: DRNA , ALKS , AZN , ALXN ,

Shares of Alkermes plc (NASDAQ:ALKS) have been assigned a consensus recommendation of Hold from the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The []

Zacks Investment Research downgraded shares of Alkermes (NASDAQ:ALKS) from a strong-buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. They currently have $26.00 price objective on the stock. According to Zacks, Alkermes earnings beat estimates in Q3 while revenues missed the same. Vivitrol and Aristada continue to drive growth []

Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

Johnson & Johnson partly ended two licensing agreements with the company.

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appear

Alkermes plc. (ALKS) CEO Richard Pops on Q3 2021 Results - Earnings Call Transcript